In this study, we identified SQ, baseline %DLCO, and SP‐D levels as potential risk factors for the development of severe pneumonitis in patients receiving first‐line nivolumab plus ipilimumab with or without chemotherapy. The gene discussed is SFTPD; the disease is pneumonitis.